2018 AAD Annual Meeting

2018 AAD Annual Meeting American Academy of Dermatology 16-20 FEBRUARY 2018 • SAN DIEGO • USA EVIEWED R PEER- CONFERENCE CONFERENCE REPORT Late Breakers Atopic Dermatitis Spotlight on Acne New agents are in the pipeline for Sleep disturbance is an AD co- Not only AD patients, also acne the treatment of moderate to severe morbidity, which is often over- patients have a barrier defect. atopic dermatitis: The JAK inhibitor looked, but always warrants step Therefore, patients benefit from upadacitinib showed promising up therapy. New study data hint the use of suitable moisturisers results, but also dual JAK/SYK in- to the fact that antihistamines that should always be recom- hibition is an interesting option. should be used more critically in mended by the dermatologist. minors. read more on PAGE 3 read more on PAGE 12 read more on PAGE 15 Editor Prof. dr. Peter van de Kerkhof, University Medical Centre, Radboud, The Netherlands MEDIC AL PUBLISHERS Letter from the Editor Prof. Peter van de Kerkhof Dear Reader, Biography Peter van de Kerkhof is It is my pleasure to present the report on 2018 -AAD Professor in Dermatology and Chairman of the Department Annual meeting held in San Diego, USA on February 16- of Dermatology of the University 20. The Meeting was a huge success and the programme Medical Centre St. Radboud, covered all aspects of dermatology, incorporating both Nijmegen. Professor van de explorative research and clinical studies. Kerkhof graduated in Medicine from the Catholic University of This report compiles several studies from late breaker Nijmegen in 1978 and trained in Dermatology at the Radboud session, Psoriasis, Atopic dermatitis, Acne management, University Nijmegen Medical Alopecia Areata, Melanoma related to risk-factor Centre, Nijmegen. Since his identification, innovative therapeutic approaches, first publication on psoriasis in presented in this meeting. We have selected the 1980, Professor van de Kerkhof clinically relevant topics and key outcomes that may be has kept a long-standing most interest to the practicing clinicians. commitment to research on the pathogenesis and treatment of psoriasis. He serves as I hope that you enjoy our selections. Editor or Associated Editor for 7 dermatological journals and With best regards, has published over 700 Peter publications in peer-reviewed journals. Professor van de Kerkhof is a member of 12 international dermatology organisations and is past President of the European Society for Dermatological Research, the European Dermatology Forum and the International Psoriasis Council. CONFERENCE REPORT - AAD 2018 Contents Letter from the Editor Interview with Dr. Erik Joseph Stratman 3 Late Breakers 3 IL-17C Inhibition in AD: a new treatment approach 3 But also new oral treatments on the horizon 4 First promising data for a dual JAK/SYK inhibitor COLOPHON 4 Proof of concept trial regarding anti-IL-33 blockade 4 Psoriasis: unprecedented activity with selective IL-23 blocker Editor Prof. dr. Peter van de Kerkhof 5 Analysis of the VOYAGE-2-trial: a first glimpse into disease Radboud University Medical Centre, The Netherlands modification? Advisory Board Dr. Pierre Vereecken, MD, PhD 5 Dual IL-17 inhibitor active in patients with moderate-to-severe Psoriasis CLIDERM Clinics Dermatology, Belgium 6 Ustekinumab lowers risk of aortic inflammation 6 Soft molecule highly efficacious in hyperhidrosis Editorial Manager Lisa Colson 7 Anticholinergic towelettes safe and effective in paediatric hyperhidrosis Editorial Co-ordinators Nalinee Pathak, MSc. 7 Apremilast effective in Behcet´s Syndrome Bas Braakman, MSc. Executive Publisher Rene Draper, MSc. 8 First specific therapy for patients with Hidradenitis suppurativa Medical Writer Dr. Susanne Kammerer 9 Psoriasis: An Update Production Manager Desiree Heijl 9 Supersaturation to enhance topical therapy Graphic Design MOOZ grafisch ontwerp 10 Excimer laser treats faster than UVB box 10 Spoiled for choice regarding biologics in psoriasis 11 New selective IL-23 blockers All rights reserved. No part of this publication may be reproduced, distributed, or transmitted 11 Psoriasis management online? in any form or by any means, including photocopying, recording, or other 12 What´s Hot in Atopic Dermatitis electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical 12 Are we too comfortable using antihistamines? reviews and certain other noncommercial uses permitted by copyright law. 12 Sleep disturbances warrant step-up therapy Copyright ©2018 Medicom Medische Uitgeverij BV 12 Osteoporosis: another neglected AD comorbidity 13 New topical and systemic treatments Disclaimer: The ideas and opinions expressed in this journal or other associated 14 IL-4/IL-13 inhibition: key factor in the AD pathogenesis publications do not necessarily reflect those of Medicom Medical Publishers. Although great care has been taken in compiling the content 14 Even non-responders benefit from the treatment of this publication, Medicom is not responsible or liable in any way for the 14 Significant itch reduction currency of the information, for any errors, omissions or inaccuracies in the original articles, or for any consequences arising from the content. Approved 15 Acne Management: Generous with Moisturiser, Restrictive with product information should be reviewed before prescribing. The mention of Antibiotics any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of 15 Acne often worsens in winter the treating physician or other health care provider, relying on independent 15 Early therapy prevents scarring experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check 16 Restrictive antibiotic use to fight resistance the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify 16 Novel tetracycline effective in acne the dosage, method, and duration of administration, or contraindications. 17 Alopecia Areata: A Glimpse into the Future Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. Medicom assumes no 17 Many new agents in the pipeline responsibility for any injury or damage to persons or property arising out of 18 Combination therapy to enhance topical steroids or related to any use of the material contained in this publication or to any 18 Melanoma: A Growing Disease Burden in Europe errors or omissions. 18 Atypical lesions in paediatric patients 19 Lower melanoma risk in coffee addicts? 19 Better diagnosis with deep convolutional neural networks 19 Survival benefit of targeted combination therapy MEDIC AL PUBLISHERS 20 Pearls of the Posters 20 Better gastrointestinal tolerability with biologics than the Postal address Head Office conventional therapy Medicom Medical Publishers Medicom Medical Publishers 21 Improvement in impact of genital psoriasis on sexual activity with PO Box 90 Faas Eliaslaan 5 use of ixekizumab Zipcode 3740 AB 3742 AR Baarn 21 Intralesional cryosurgery effective for keloids City Baarn The Netherlands 21 Itching in psoriasis- more important than often thought Country The Netherlands Telephone +31 85 4012 560 Join us on LinkedIn Fax +31 85 4012 569 MEDIC AL PUBLISHERS E-mail [email protected] ISSN 2468-8762 18:3 Interview with Dr. Erik Joseph Stratman Marshfield Clinic, Marshfield, chair of the AAD Scientific Assembly Committee Interview taken on 17 February 2018 by Susanne Kammerer Living in the golden age of psoriasis and atopic dermatitis therapies "What are the highlights from AAD 2018? How should we select the right treatment for a patient? " Dr. Stratman: “First of all, it is very exciting that we have one Dr. Stratman: “I am sure that there is some variability across of the largest groups of registrants ever, with physicians from the globe on how that happens but, in most places in the US, every state in the US and over 99 other countries. As for the insurance companies that are usually the ones paying for highlights, we are surely living in the golden age of psoriasis medicines or helping the patient pay for the medicines often therapies. There is a large number of new psoriasis drugs and want you to go through a step ladder approach with the more as dermatologists want to learn about new therapies, that is expensive drugs being higher up. So, most of the time we do certainly one of the hot areas. Furthermore, new therapies for start with frontline therapy that may have been around a little very severe atopic dermatitis (AD) are being discussed. There while longer. Many of the more expensive therapies are second- are also some practice management topics dermatologists line. In my opinion, the great news is that we have so many have to face; for example, access to drugs which are becoming options. Even if we go through the therapies that are lower on incredibly expensive over the last five to ten years. We have to the ladder, if they don’t work there are many more choices, and ask why they have to be so expensive and what can we do to I think this variety of choices is what will help drive the prices get access to those therapies for our patients. The “hot topics down. It is just the market forces of drugs sales.” in dermatology” are also very popular as this session looks at new developments in a variety of different areas like drug What is your wish for future AAD meetings? therapy, disease management, diagnosis and basic science. Dr. Stratman: “My idea of a meeting is one where physicians Those are always very exciting because we learn not only leave the meeting and immediately have an impact in how about what’s ready for practice today but what’s coming down they practice medicine. There are many studies that show the pipeline. In addition, the well-being of dermatologists that if you attend a meeting not doing anything but sit in a seat is discussed as we are facing increasing rates of burnout and listen to lectures, this won’t change much or anything that amongst our colleagues.” you will do in your practice.

Load more